FDA-BLA761234
Document details
Summary
OPDUALAG, an intravenous injectable drug, will likely receive a specific J-code for Medicare billing due to its status as a new molecular entity. Since it is an oncology drug, it may be eligible for pNew oncology drug OPDUALAG may impact Medicare billing.
Affected specialty
Oncology alerts →Source document
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdfCLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA022437 · Oncology
Trelstar (triptorelin pamoate) is an intramuscular injectable GnRH agonist indicated for advanced prostate cancer, billing under Medicare Part B as a physician-administered drug. As an established inj
View alertPolicy FDA-NDA021288 · Oncology
Trelstar (triptorelin pamoate) is an intramuscular injectable approved for a new dosage form under NDA021288, placing it firmly in the Medicare Part B billing pathway as a physician-administered drug.
View alertPolicy FDA-NDA020715 · Oncology
Trelstar (triptorelin pamoate) is an intramuscular injectable indicated for prostate cancer, placing it squarely in the Medicare Part B billing pathway as a physician-administered drug. It is typicall
View alertPolicy FDA-NDA219304 · Oncology
Romvimza (vimseltinib) is an oral capsule kinase inhibitor approved via NDA219304, placing it squarely in the Medicare Part D billing pathway as a self-administered outpatient drug. As a new molecular
View alert